News
REPL
6.33
-1.40%
-0.09
Weekly Report: what happened at REPL last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at REPL last week (0408-0412)?
Weekly Report · 04/15 09:08
Weekly Report: what happened at REPL last week (0401-0405)?
Weekly Report · 04/08 09:08
Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024
In the study, treatment with RP1 as monotherapy resulted in an overall response rate of 34.8 percent. There was no evidence of allograft rejection. The safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers.
Benzinga · 04/08 06:21
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ transplants. The results were presented at the AACR 2024 Annual Meeting in San Diego. Replimune Group, Inc. Is a clinical stage biotechnology company.
Barchart · 04/07 16:00
Replimune Group: Statement of changes in beneficial ownership of securities
Press release · 04/04 00:31
Weekly Report: what happened at REPL last week (0325-0329)?
Weekly Report · 04/01 09:08
Analysts Are Bullish on Top Healthcare Stocks: Replimune Group (REPL), Merck & Company (MRK)
TipRanks · 03/27 07:40
Replimune Names Sushil Patel as CEO in Broader Shakeup
Replimune Group, a clinical-stage biotechnology company, named Sushil Patel as its next chief executive officer. Patel will succeed Philip Astley-Sparke, who will become executive chairman. The company is nearing commercialization of one of its drugs.
Dow Jones · 03/26 11:44
Replimune Group Announces Major Executive Team Overhaul
TipRanks · 03/26 11:42
Replimune Group announces CEO transition
Replimune Group, Inc. Announces CEO transition. Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024. Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.
Seeking Alpha · 03/26 11:37
Press Release: Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024.
Dow Jones · 03/26 11:30
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Barchart · 03/26 06:30
Weekly Report: what happened at REPL last week (0318-0322)?
Weekly Report · 03/25 09:08
Possible Bearish Signals With Replimune Group Insiders Disposing Stock
Replimune Group, Inc. Insiders sold their shares over the last year. The biggest insider sale was by the CEO & Director of the company, Philip Astley-Sparke, for US$323k. In the last 12 months, Replimune group insiders didn't buy any shares. But the company does have a high insider ownership of 6.7% of the stock. It's not a good sign for shareholders to see multiple insider transactions at the same company. ReplimUNE Group has had no insider transactions in the last quarter.
Simply Wall St · 03/21 10:01
Weekly Report: what happened at REPL last week (0311-0315)?
Weekly Report · 03/18 09:08
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
NASDAQ · 03/11 13:55
Weekly Report: what happened at REPL last week (0304-0308)?
Weekly Report · 03/11 09:08
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
NASDAQ · 03/08 17:00
More
Webull provides a variety of real-time REPL stock news. You can receive the latest news about Replimune Group through multiple platforms. This information may help you make smarter investment decisions.
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.